Related Articles
Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi‑institute study
Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy Corrigendum in /10.3892/mco.2021.2317